CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology, Inc. has an updated institutional ownership disclosure showing that a group of affiliated Wellington entities reports beneficial ownership of CG Oncology common stock. Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP collectively report beneficial ownership of 5,324,751 shares of common stock, representing 6.04% of the class.
The Wellington entities report 0 shares with sole voting or dispositive power and instead list shared authority: up to 4,637,354 shares with shared voting power and up to 5,324,751 shares with shared dispositive power, depending on the specific entity. The shares are held of record by clients of various Wellington investment advisers, which are controlled through a parent holding company structure headed by Wellington Management Group LLP. Those clients have rights to dividends and sale proceeds, and no individual client is reported to hold more than five percent of the class.
CGON received a notice of proposed sales of common stock by shareholder Ambaw Bellete under a resale filing. The plan lists up to 32,137 common shares to be sold through Morgan Stanley Smith Barney LLC’s Executive Financial Services, tied to a stock option exercise dated 08/12/2026, with an aggregate market value of $2,526,514.53. The shares are listed on NASDAQ. Over the prior three months, Bellete reported multiple open‑market sales of CGON common stock, including 75,000 shares on 08/06/2026 for $5,672,212.50 and 50,000 shares on 08/11/2026 for $3,810,255.00, along with several other transactions in late July and early August 2026.
CGON insider Ambaw Bellete plans to sell up to 50,000 shares of common stock, expected on August 11, 2026, via a stock option exercise settled in cash through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
The disclosure also lists multiple recent sales of CGON common stock by Ambaw Bellete between July 15 and August 10, 2026, each with specified share amounts and dollar values.
CGON filed a Form 144 for the potential sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with a proposed sale date of August 10, 2026 tied to a stock option exercise. The filing also lists multiple common stock sales by Ambaw Bellete over the past three months, each with specified share amounts, dates, and dollar values.
CGON insider Ambaw Bellete has filed a Form 144 indicating an intention to sell up to 9,250 shares of common stock through Morgan Stanley Smith Barney LLC, with a proposed sale date of August 7, 2026. The filing also lists several substantial common-stock sales completed over the prior three months.
Ambaw Bellete filed to sell 75,000 shares of CGON common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services program on NASDAQ, related to a stock option exercise dated August 6, 2026. The filing also lists multiple prior common stock sales by Bellete over the past three months with substantial dollar values.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec for bladder cancer and reported continuing losses as it invests in late-stage trials. For the three and six months ended June 30, 2026, net losses were $79.1 million and $139.3 million, respectively, with no approved products yet generating sales.
Cretostimogene is being advanced across multiple Phase 2 and Phase 3 studies in non-muscle invasive bladder cancer, including BOND-003, where monotherapy data showed a 75.5% complete response rate and 12- and 24-month duration of response rates of 64.2% and 60.1%, supporting a planned Biologics License Application in the fourth quarter of 2026.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $1,028.3 million, with working capital of $1,002.4 million, which management believes will fund operations for at least 12 months. A Delaware jury verdict, upheld by a July 2026 order, eliminated a potential 5% royalty on future cretostimogene sales and left ANI Pharmaceuticals without damages.
CG Oncology, Inc. reported second quarter 2026 results and expanded its equity financing capacity. For the quarter ended June 30, 2026, total revenues were $1,157 thousand and net loss was $79,056 thousand, or $0.90 per share, driven mainly by higher research and development and general and administrative expenses.
Cash, cash equivalents and marketable securities totaled approximately $1.0 billion as of June 30, 2026, which the company expects will fund operations through 2029. CG Oncology continues late‑stage development of cretostimogene grenadenorepvec, with Phase 3 PIVOT‑006 topline data anticipated in the near term and completion of a BLA for high‑risk BCG‑unresponsive NMIBC targeted for the fourth quarter of 2026. Phase 3 BOND‑003 Cohort C results were published in The Lancet Oncology, and a Delaware court denied ANI’s post‑trial motions, leaving in place a prior jury verdict favorable to CG Oncology.
Separately, CG Oncology filed Amendment No. 2 to its prospectus under an Open Market Sale Agreement with Jefferies, increasing the amount of common stock that may be sold under the at‑the‑market program by up to $500.0 million, after previously registering and selling approximately $550.0 million of shares.
CG Oncology is amending its existing at-the-market common stock program with Jefferies to increase the aggregate offering capacity by an additional $500.0 million, bringing the total potential offering size to $1,050.0 million of common stock under its Form S-3ASR shelf. The company has already sold 10,800,525 shares for gross proceeds of approximately $550.0 million under the sales agreement.
Sales may be made from time to time as an “at the market offering” through Jefferies, which will earn up to 3.0% of gross proceeds. An illustrative scenario assumes selling 6,904,170 shares at $72.42 per share, implying immediate dilution of $55.92 per share to new investors versus an as adjusted net tangible book value of $16.50 per share. Net tangible book value as of March 31 2026 was $1,080.9 million, or $12.28 per share.
CGON insider Ambaw Bellete filed a notice to sell up to 25,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $1,837,500.00, on or after August 5, 2026 on NASDAQ. These shares are tied to a stock option exercise paid in cash on the same date.
The filing also lists recent sales of CGON common stock during the prior three months by Ambaw Bellete, including 52,438 shares for $3,816,007.65 on July 15, 2026, and additional transactions on July 23, 27, 28, and 29, 2026 with share amounts ranging from 4,303 to 50,000 shares.